Health disparities in diabetes treatment: The challenge of G6PD deficiency
Authors' conclusion
This research highlights serious gaps in the management of G6PD-deficient patients with diabetes, who suffer from insufficient medication management and higher rates of complications. These findings underscore the need to account for G6PD deficiency in diabetes treatment to ensure equitable and effective healthcare for this vulnerable population.
Study context
- Population
- Patients within a national health organization, G6PD-deficient vs matched controls, followed over two decadesmatched cohort
- Exposure
- G6PD-deficient patients vs matched controls without G6PD deficiency
- G6PD-deficientn = 3,913
- Outcome
- HbA1c levels, patterns of diabetes medication purchases, and incidence of severe diabetes-related complications
- Follow-up
- Over two decades
Methodological detailsnational health organization, two decades
- National health organization
- Two decades
Main finding
As reported in the abstract
Severe diabetes-related complications
Each group vs controlsEstimate (95% CI)
G6PD-deficient
aHR, severe kidney insufficiency 1.44(1.16–1.81)
G6PD-deficient
aHR, MI 1.75(1.23–2.49)
G6PD-deficient
aHR, neuropathy 1.27(1.02–1.58)
Observational data: associations, not effects.
Original publication
Health disparities in diabetes treatment: The challenge of G6PD deficiency. Diabetes Res Clin Pract. Published 20 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →